Summary#
H.R. No. 1495, “Suspending limitations on conference committee jurisdiction, S.B. No. 2308,” is a House resolution, not a bill that itself changes state law. It suspends parts of House Rule 13 so the conference committee on S.B. 2308 can consider and act on specified changes. Its stated goal is to let the committee resolve differences on a bill about ibogaine clinical trials.
- The resolution lets the committee consider removing a proposed grant program, its rules and application process, and a proposed selection committee.
- It lets the committee consider a consortium made up of at least one drug developer, one institution of higher education, and one hospital. The proposed version would let the Health and Human Services Commission (HHSC) select a consortium in its sole discretion.
- It lets the committee consider requiring HHSC to contract with the selected consortium’s lead university or college and provide funding. The proposed contract would set goals, budget, timeline, collaborating entities, and the state’s share of revenue. State funds could not be paid out until non-state matching funds are received and verified.
- It lets the committee consider requiring proposals to cover trial design and safety, intellectual property, a Texas business presence, insurance coverage, access for uninsured people, provider training, and matching-fund capacity.
- It also lets the committee consider quarterly progress and financial reports, a yearly HHSC report to the Legislature, and a requirement that at least 20% of revenue from specified commercial and intellectual-property rights go to the state.
These are changes the committee was allowed to consider—not changes made by H.R. 1495 itself. The supplied record says the House adopted the resolution on June 1, 2025, but does not establish the final status or wording of S.B. 2308.
What it means for you#
- General public: H.R. 1495 itself does not establish ibogaine trials, create a treatment service, or change anyone’s eligibility for treatment.
- Researchers, hospitals, universities, and drug developers: The resolution itself creates no duties for you. If its proposed changes became part of S.B. 2308, a consortium would need all three types of members, and only a university or hospital could be a trial site.
- Taxpayers: The resolution itself does not appropriate money. The proposed S.B. 2308 changes would allow HHSC to fund a selected consortium under a contract, with non-state matching funds required before state funds are disbursed.
- People seeking treatment: The proposed changes would require a consortium proposal to address access for uninsured people and plans for payer coverage and provider training. They do not guarantee that treatment would be approved, offered, covered, or available.
Money#
No cost estimate is provided in the available material; H.R. 1495 itself does not appropriate funds.
- The proposed changes to S.B. 2308 would require HHSC to contract to provide funding to a selected consortium, but do not state an amount.
- The consortium would have to show capacity to match state funding with non-state funds; HHSC could not disburse state funds until it verified receipt of matching funds.
- The proposed contract would set the state’s share of revenue, and the proposed law would allocate at least 20% of covered commercial-rights revenue to the state. The amount and timing of any such revenue are not provided.
What is unclear#
- The supplied material does not show whether the conference committee included these changes in the final S.B. 2308 or whether that bill became law.
- The resolution does not itself establish the consortium, set its funding, or create a process for selecting it.
- The proposed text leaves the amount of state funding, the detailed selection criteria, and the meaning of some terms—such as “demonstrates efficacy”—unclear.
- The material does not explain how the proposed state commercial interest in intellectual property would work alongside the proposed revenue allocation.
Case for#
- A possible argument for the resolution is that it gives the conference committee room to assemble a workable version of S.B. 2308 from the House and Senate versions.
- The proposed changes set out a possible structure for trials: a consortium with specified types of members, a detailed proposal, safety plans, and financial reporting.
- Requiring non-state matching funds and allowing payments in stages tied to objectives could limit payment before funds and progress are verified.
Case against#
- The resolution allows the committee to consider substantial changes not included in either chamber’s version, including removing the grant program and adding new consortium, funding, and revenue rules.
- The proposed version gives HHSC sole discretion to select a consortium, but the supplied text does not set out detailed selection criteria or an appeal process.
- The proposed funding duty has no amount or cost estimate in the supplied material.
- The proposed intellectual-property and revenue provisions may leave important details for the contract or consortium agreements, including how rights and revenue would be divided in practice.